2019 Montelukast Intermediate Market Size, Key Companies, Technology and Trends

Montelukast Intermediate Market Overview 

The Montelukast Intermediate Market is estimated to be valued at USD 4,794.763 thousand by 2023 and Expected to register CAGR of 4.34% During the Forecast Period. The Global Montelukast Intermediate Market has been evaluated as a moderately growing market, and it is expected that the market will continue to grow similarly in the near future. Factors characterizing the market growth are worldwide rising prevalence of asthma, bronchospasm, allergic rhinitis, and urticaria, burgeoning pharmaceutical industry coupled with the increasing demand from API manufacturers, and montelukast patent expiration along with the increasing presence of generics. burgeoning pharmaceutical industry coupled with the increasing demand from active pharmaceutical ingredients (APIs) manufacturers, and montelukast patent expiration along with the increasing presence of generics.

All the major players are competing with each other to capture a major stake of the market. Other small companies are also holding a small but marginal share in this market. following are the companies in the global Montelukast Intermediate market that includes • Lonza • Merck KGaA • Oxford BioMedica • Spark Therapeutics Inc. • FinVector Vision Therapies • Novasep • FUJIFILM Diosynth Biotechnologies U.S.A. Inc • Brammer Bio and uniQure N.V.

However, the only bottleneck in a growth trajectory of the global Montelukast Intermediate market is the presence of stringent regulatory policies and the high cost of manufacturing building blocks for active pharmaceutical ingredients. Segment Analysis The global Montelukast Intermediate market, by application, can be classified into three types, namely, asthma, allergic rhinitis, bronchospasm, and urticaria.

Key Findings of the Study: 

• Global Montelukast Intermediate Market is projected to reach over 4,794.763 Thousand by 2023 with 34% CAGR during the review period of 2018-2023.
• Americas accounted for the largest share due to the rising prevalence of asthma and allergic rhinitis in the US and Canada and increasing research and development activities related to the pharmaceutical intermediates.
• Asthma segment by application is projected to value 65 thousand in 2023. 

Get a Free Sample at https://www.marketresearchfuture.com/sample_request/7887

Regional Analysis On the basis of region, the global montelukast intermediate market has been divided into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. •

North America o US o Canada •
Europe o Germany o Russia o France o Italy o UK o Rest of Europe •
Asia-Pacific o China o India o Japan o Rest of Asia-Pacific •
Latin America o Brazil o Mexico o Argentina o Rest of Latin America •
Middle East & Africa